Global Blood To Discontinue GBT 440 Program For Idiopathic Pulmonary Fibrosis

(RTTNews) - Global Blood Therapeutics, Inc. (GBT) Monday announced the discontinuation of its GBT440 program for the treatment of idiopathic pulmonary fibrosis or IPF. GBT said it intends to make no further investments in additional clinical studies plans to stop further enrollment in any ongoing studies.

The company noted that the decision is based on results from three proof-of-concept studies including a Phase 1 study in healthy volunteers called Basecamp and two Phase 2a studies in patients with IPF called GBT440-006 and ZEPHYR.

Ted Love, president and chief executive officer of GBT said the data from these proof-of-concept studies did not demonstrate sufficient overall clinical benefit to justify continuing the program.